UNSPSC 51352425: Estradiol/hydroxyprogesterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352425 Estradiol/hydroxyprogesterone is a Commodity code covering prescription pharmaceutical products, specifically hormone-replacement and progestin formulations that state and local health agencies procure through pharmaceutical benefit programs, cooperative purchasing alliances, and direct-to-manufacturer contracting initiatives. State health departments and multistate cooperative purchasing organizations dominate the issuing-body mix, with the Texas Health and Human Services Commission and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing the most recent high-profile buyers. The work spans both traditional wholesaler-mediated supply arrangements and emerging direct-contracting models that bypass pharmacy benefit managers and group purchasing organizations to negotiate net pricing and outcomes-based agreements with manufacturers. Vendors responding under this code must typically hold current Good Manufacturing Practices certification, comply with Drug Supply Chain Security Act requirements, maintain relationships with authorized pharmaceutical wholesalers, and demonstrate pricing flexibility across multiple pricing models including flat-rate, net-price, and WAC-minus structures.

Texas HHS issued a Request for Information (RFI No. HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's interest in restructuring how it acquires pharmaceuticals outside traditional PBM and wholesaler channels. MMCAP, the Minnesota cooperative purchasing vehicle serving multiple states including Oregon, issued a more conventional Request for Proposal (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen, Cardinal Health, and Morris & Dickson—with contract effectiveness targeted for July 1, 2026. Activity under this code is concentrated in the Upper Midwest and South, with Texas and Minnesota representing the primary procurement hubs in recent months; vendors must prepare for both direct manufacturer engagement and traditional wholesaler-intermediated supply models depending on the issuing jurisdiction's strategic direction.